[(Trimethylsilyl)cyclopropenyl]rifampicinium—A Novel Antitubercular Antibiotic Active Versus NIAID Category A/B Priority Pathogens

Rifampicin was selectively quaternized at the distal methyl piperazine nitrogen with the chemical compound 3-bromo-1-(trimethylsilyl)-1-propyne in >99% purity. A nitrogen ylide-driven rearrangement finally left isolated 4′-[(1S)-2-(trimethylsilyl)cycloprop-2-en-1-yl]rifampicinium-4-olate (TPR). The intermediate product 4′-[3-(trimethylsilyl)prop-2-yn-1-yl]rifampicinium-4-olate was not isolable. TPR was tested against the Mycobacterium tuberculosis laboratory strain H37Rv, and against a panel of six clinical isolates of M. tuberculosis covering acquired resistance towards isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, kanamycin A, amikacin, capreomycin/viomycin, and ethionamide/prothionamide. TPR was (3.7–1.8)-fold (molar) more potent than rifampicin against M. tuberculosis H37Rv, and was elucidated to act bactericidal, extra- and intracellularly, and under low-oxygen conditions versus M. tuberculosis, while exerting no cell cytotoxicity. TPR was highly active against an MDR-TB clinical isolate carrying the bacterial DNA-dependent RNA polymerase β subunit enzyme protein RpoB Asp435(516)Val mutation conferring resistance to rifampicin. TPR in co-administration with the steroidal (gluco)cortico(stero)id nuclear receptor antagonist ORG34517 was highly active versus Staphylococcus aureus (MSSA and MRSA) and Streptococcus pneumoniae [including penicillin- and (lev)ofloxacin-resistant isolates]. Bacillus sp. are very susceptible to TPR, predicting TPR’s activity towards sporulating B. anthracis (anthrax). In the Gram-negative sector, TPR showed high activity versus drug-sensitive Neisseria gonorrhoeae, Vibrio cholerae serogroup O1 biovar El Tor serotype Inaba, and Liberibacter crescens BT-1T. TPR showed remarkable in vivo activity against Francisella tularensis, far superior to the resistance-inducing and disease-relapse-suffering rifampicin. The efficacious in vivo activity of TPR versus F. tularensis Schu S4 was shown to be synergistic with doxycycline, to be devoid of any induction of resistance development, and to evoke 100% cure of murine tularemia without any disease relapse off-treatment. The superior antimicrobial in vivo activity of TPR in comparison to rifampicin (and other antibiotics) is proposed to rely on covalent inactivation of the bacterial DNA-dependent RNA polymerase β subunit RpoB enzyme protein by the TPR aromatic split-off product (trimethylsilyl)cyclopropen(yl)ium.

Authors

Institutions

Publication Details

Journal
Molecules
Published
2026-11-18
DOI
https://doi.org/10.3390/molecules31224187
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

[(Trimethylsilyl)cyclopropenyl]rifampicinium—A Novel Antitubercular Antibiotic Active Versus NIAID Category A/B Priority Pathogens

Andreas J. Kesel, Mourad Zerfaoui, Raymond F. Schinazi, Adam Hundhammer
1 links
Molecules
Tuberculosis Research and Epidemiology
article

[(Trimethylsilyl)cyclopropenyl]rifampicinium—A Novel Antitubercular Antibiotic Active Versus NIAID Category A/B Priority Pathogens

Andreas J. Kesel, Mourad Zerfaoui, Raymond F. Schinazi, Adam Hundhammer
article en

Abstract

Rifampicin was selectively quaternized at the distal methyl piperazine nitrogen with the chemical compound 3-bromo-1-(trimethylsilyl)-1-propyne in >99% purity. A nitrogen ylide-driven rearrangement finally left isolated 4′-[(1S)-2-(trimethylsilyl)cycloprop-2-en-1-yl]rifampicinium-4-olate (TPR). The intermediate product 4′-[3-(trimethylsilyl)prop-2-yn-1-yl]rifampicinium-4-olate was not isolable. TPR was tested against the Mycobacterium tuberculosis laboratory strain H37Rv, and against a panel of six clinical isolates of M. tuberculosis covering acquired resistance towards isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, kanamycin A, amikacin, capreomycin/viomycin, and ethionamide/prothionamide. TPR was (3.7–1.8)-fold (molar) more potent than rifampicin against M. tuberculosis H37Rv, and was elucidated to act bactericidal, extra- and intracellularly, and under low-oxygen conditions versus M. tuberculosis, while exerting no cell cytotoxicity. TPR was highly active against an MDR-TB clinical isolate carrying the bacterial DNA-dependent RNA polymerase β subunit enzyme protein RpoB Asp435(516)Val mutation conferring resistance to rifampicin. TPR in co-administration with the steroidal (gluco)cortico(stero)id nuclear receptor antagonist ORG34517 was highly active versus Staphylococcus aureus (MSSA and MRSA) and Streptococcus pneumoniae [including penicillin- and (lev)ofloxacin-resistant isolates]. Bacillus sp. are very susceptible to TPR, predicting TPR’s activity towards sporulating B. anthracis (anthrax). In the Gram-negative sector, TPR showed high activity versus drug-sensitive Neisseria gonorrhoeae, Vibrio cholerae serogroup O1 biovar El Tor serotype Inaba, and Liberibacter crescens BT-1T. TPR showed remarkable in vivo activity against Francisella tularensis, far superior to the resistance-inducing and disease-relapse-suffering rifampicin. The efficacious in vivo activity of TPR versus F. tularensis Schu S4 was shown to be synergistic with doxycycline, to be devoid of any induction of resistance development, and to evoke 100% cure of murine tularemia without any disease relapse off-treatment. The superior antimicrobial in vivo activity of TPR in comparison to rifampicin (and other antibiotics) is proposed to rely on covalent inactivation of the bacterial DNA-dependent RNA polymerase β subunit RpoB enzyme protein by the TPR aromatic split-off product (trimethylsilyl)cyclopropen(yl)ium.

MoleculesVol. 31(22)
Emory University (US), Children's Healthcare of Atlanta (US), Technical University of Munich (DE)
U.S. Department of Veterans Affairs, Emory University, University College London, School of Medicine, Emory University, Center for AIDS Research, University of Washington
Good health and well-being
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon